The serine protease granzyme B (GrB) of cytotoxic lymphocytes efficiently induces apoptosis by direct activation of caspases and cleavage of central caspase substrates. We employed human GrB as an effector function in chimeric fusion proteins that also contain the EGFR ligand TGFα or an ErbB2-specific single-chain antibody fragment (scFv) for selective targeting to tumor cells. GrB-TGFα (GrB-T) and GrB-scFv(FRP5) (GrB-5) molecules expressed in the yeast Pichia pastoris were bifunctional, cleaving synthetic and natural GrB substrates, and binding specifically to cells expressing EGFR or ErbB2 target receptors. Upon cell binding the chimeric molecules were internalized into intracellular vesicles, but could be released into the cytosol by the endosomolytic reagent chloroquine. Treatment with picomolar to nanomolar concentrations of GrB-5 and GrB-T resulted in selective and rapid tumor cell killing, accompanied by clear signs of apoptosis such as chromatin condensation, membrane blebbing, formation of apoptotic bodies and activation of endogenous initiator and effector caspases.
Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are highly specialized effectors of the immune system, which are able to recognize and eliminate virus-infected or transformed cells. Upon contact with their targets, they secrete the contents of cytotoxic granules, which efficiently induce apoptotic cell death within minutes to a few hours.1, 2 Together with the pore-forming protein perforin, the serine-protease granzyme B (GrB) was recognized as the most potent effector molecule present in these cytotoxic granules.3 Thereby perforin is required to allow GrB access to substrate proteins inside target cells by mediating its release from intracellular vesicles, where the protease accumulates after uptake.4 GrB is the only serine protease known to date that shares the substrate specificity of caspases, and cleaves its substrates after specific aspartate residues.5 Once inside the cytosol of a target cell, GrB induces apoptosis by mimicking caspase activity and activating caspase-3 and other caspases.6, 7, 8, 9, 10 In addition, GrB was found to cleave central caspase substrates,11 such as the BH3-only protein Bid12, 13 and the inhibitor of the caspase-activated DNase (ICAD).14
Here, we have employed recombinant human GrB to selectively eliminate tumor cells that express the epidermal growth factor receptor (EGFR) or the closely related ErbB2 (HER2) receptor tyrosine kinase. EGFR and ErbB2 overexpression have been found in many tumors of epithelial origin, and have been shown to contribute to cellular transformation.15, 16 These growth factor receptors are accessible from the extracellular space, making them attractive targets for monoclonal antibodies (mAbs),17 and antibody-derived reagents such as immunotoxins.18 For targeting to EGFR and ErbB2, we fused the proapoptotic protease GrB to the ErbB2-specific single-chain antibody fragment (scFv) scFv(FRP5),19 or to transforming growth factor α (TGFα)20 as a natural EGFR ligand. In previous attempts to utilize GrB as an apoptosis-inducing effector, recombinant derivatives were expressed in Escherichia coli as inactive precursors, requiring in vitro cleavage after purification from bacterial lysates to yield enzymatically active GrB molecules.21, 22, 23 This necessity for in vitro activation might explain the more moderate cytotoxic activities described for these molecules. We have followed a different strategy expressing the chimeric GrB molecules as secreted proteins in the yeast Pichia pastoris without the need for refolding or in vitro activation. GrB-scFv(FRP5) (GrB-5) and GrB-TGFα (GrB-T) molecules purified from yeast culture supernatants retained enzymatic GrB activity, and in the presence of an endosomolytic reagent displayed high and selective cytotoxicity towards tumor cells expressing the respective target receptors.
Chimeric GrB fusion proteins are expressed in P. pastoris at high yields
cDNA encoding mature human GrB (amino-acid residues 21–247) was fused via a (Gly4Ser)4-His6 linker to sequences encoding the ErbB2-specific scFv antibody fragment scFv(FRP5), or the natural EGFR ligand TGFα in the yeast expression vector pPIC9 (Figure 1a). In the resulting expression plasmids pPIC9-GrB, pPIC9-GrB-5 and pPIC9-GrB-T, expression of mature GrB and GrB-scFv(FRP5) (GrB-5) and GrB-TGFα (GrB-T) fusion proteins carrying C-terminal myc and His6 tags is controlled by the methanol-inducible alcohol oxidase AOX1 promoter, and the gene products are secreted into the culture supernatant via the α-factor signal sequence from Saccharomyces cerevisiae. During secretion, this signal peptide is cleaved off, producing the N-terminus of mature human GrB.
Recombinant GrB derivatives were purified from culture supernatants by single-step Ni2+-affinity chromatography to 80–90% purity as judged by SDS-PAGE analysis (Figure 1b, lanes 1–3). Yields were 1–2 mg of purified proteins per liter of culture. Identity of the proteins was confirmed by immunoblot analysis with myc-tag-specific mAb 9E10 (Figure 1b, lanes 4–6). The proteins migrated with an apparent molecular mass significantly higher than calculated from the amino-acid sequences (38 versus 27 kDa for GrB; 40 versus 36 kDa for GrB-T; 70 versus 58 kDa for GrB-5). This was due to glycosylation as demonstrated by treatment of the recombinant proteins with N-glycosidase F (data not shown). As controls, inactive GrBS183A, GrBS183A-5 and GrBS183A-T mutants, which contain an alanine instead of the active site serine 183,24 were constructed and produced in P. pastoris as described above (data not shown).
Recombinant GrB derivatives cleave synthetic and physiological GrB substrates
Colorimetric assays were performed using the GrB-specific peptide substrate Ac-IETD-pNA. GrB-5 and GrB-T fusion proteins like unmodified GrB cleaved this substrate with comparable activity in a concentration-dependent manner (Figure 2a). High concentrations of the inactive mutants GrBS183A-5 and GrBS183A-T were unable to process the substrate. In addition, as a physiological GrB substrate recombinant human procaspase-3 was incubated with GrB derivatives and cleavage reactions were analyzed for production of p12 caspase-3 subunit by SDS-PAGE and immunoblotting (Figure 2b). Thereby incubation with GrB, GrB-5 and GrB-T, but not inactive GrBS183A-5 and GrBS183A-T proteins resulted in complete processing and disappearance of procaspase-3, and detection of increased amounts of the p12 subunit.
Chimeric GrB-5 and GrB-T proteins bind specifically to tumor cells
Binding of GrB-5 and GrB-T to ErbB2 and EGFR on the surface of tumor cells was investigated by FACS analysis with human MDA-MB453 cells which express high levels of ErbB2 but no detectable EGFR, and MDA-MB468 cells which highly overexpress EGFR but have no detectable ErbB2.25 After incubation with purified fusion proteins followed by myc-tag-specific mAb 9E10 and phycoerythrin-conjugated secondary antibody, strong binding of GrB-5 to MDA-MB453 cells, and of GrB-T to MDA-MB468 cells was detected, indicating functionality of the fusion proteins' cell recognition domains (Figure 2c). Only very weak binding of the fusion proteins to the respective control cells was observed, which possibly reflects interaction of the GrB domain with structures on the cell surface26, 27 (and unpublished data). Specific binding to cells expressing ErbB2 or EGFR was also found for the mutant proteins GrBS183A-5 and GrBS183A-T, but not for unmodified GrB (data not shown).
Next cell killing activity of GrB-5 and GrB-T towards tumor cells expressing the respective target receptors was analyzed. To test GrB-T, MDA-MB468 and MDA-MB453 cells were used. Cytotoxic activity of GrB-5 was evaluated using murine Renca-lacZ/ErbB2 cells expressing human ErbB2 and ErbB2-negative Renca-lacZ cells as a control.28 The cells were incubated with increasing concentrations of the fusion proteins for 14 h, before cell viability was determined in MTT assays. At concentrations up to 1 μg/ml, the chimeric GrB proteins had no effect on the survival of tumor cells irrespective of the presence of their cognate target receptors on the cell surface (Figure 2d). This indicates that specific cell recognition and enzymatic activity alone are insufficient to facilitate GrB-induced cell death.
GrB fusion proteins are internalized into intracellular vesicles
We investigated internalization of the fusion proteins in human A431 epidermoid cancer cells that express both, EGFR and ErbB2 (Figure 3a). After incubation for 2.5 h, in immunofluorescence analysis with a GrB-specific antibody the proteins were no longer detected at the cell surface, indicating efficient uptake. Instead punctuate staining within the cytoplasm was found for GrB-5 and GrB-T, suggesting localization inside vesicular structures such as endosomes. Diffuse intracellular staining indicative of cytosolic localization was not observed. To investigate whether GrB fusion proteins could induce cell death if delivered directly to the cytosol, we performed microinjection experiments with GrB-5 using Renca-lacZ cells, which are ErbB2 negative and therefore unable to internalize the protein via receptor-mediated endocytosis. After 4 h, the majority of cells that were injected with GrB-5 displayed apoptotic morphology with membrane blebbing, formation of apoptotic bodies and nuclear DNA condensation (Figure 3b). After 20 h, 68% of cells injected with GrB-5 had disintegrated into small cell fragments and could no longer be identified on the culture slides (Figure 3c). In contrast, injection of cells with the mutant protein GrBS183A-5 similar to injection with PBS had no effect (4% of apoptotic cells after 20 h; Figure 3c), confirming that induction of apoptosis was dependent on the specific activity of GrB.
GrB-5 and GrB-T selectively kill tumor cells
The basic reagent chloroquine accumulates in acidic compartments such as late endosomes and lysosomes leading to osmotic rupture of the vesicles.29 We tested whether chloroquine could release internalized GrB fusion proteins from intracellular vesicles, thereby allowing access to cytosolic GrB substrates and induction of apoptosis. As described above, EGFR expressing MDA-MB468 and ErbB2-positive Renca-lacZ/ErbB2 cells were treated with increasing concentrations of GrB-T or GrB-5 in the presence of 50 μM chloroquine. MDA-MB453 and Renca-lacZ cells served as controls. After 14 h, survival of cells was determined in MTT assays (Figure 4a). In contrast to treatment in the absence of the endosomolytic reagent, incubation of the cells with GrB-T and GrB-5 in the presence of chloroquine resulted in potent and concentration-dependent cytotoxicity towards tumor cells expressing the respective target receptors (IC50 of 10 ng/ml, corresponding to 0.25 nM for GrB-T on MDA-MB468 cells; IC50 of 20 ng/ml, corresponding to 0.29 nM for GrB-5 on Renca-lacZ/ErbB2 cells). MDA-MB453 control cells displayed a slight reduction in the number of viable cells at the highest GrB-T concentration of 1 μg/ml, which might be due to the expression of small amounts of EGFR below the detection limit of EGFR immunoblots.25 ErbB2-negative Renca-lacZ cells remained unaffected at the GrB-5 concentrations applied.
To confirm that even under conditions of effective endosome release cell killing activity of the GrB fusion proteins was strictly dependent on specific recognition of the ErbB2 and EGFR target receptors, Renca-lacZ/ErbB2 cells were incubated with GrB-5 and chloroquine in the presence of an excess of parental ErbB2-specific mAb FRP5,30 or a recombinant ErbB2 protein fragment encompassing the FRP5-binding epitope.31 Addition of the competitors markedly reduced GrB-5-induced cell killing (Figure 4b). Likewise, competition of binding of GrB-T to EGFR by the antagonistic EGFR-specific mAb C22517 resulted in a drastic reduction of its cytotoxicity towards MDA-MB468 cells. In addition to specific cell recognition, enzymatic GrB activity was required to induce cell killing (Figure 4c). The mutant proteins GrBS183A-5 and GrBS183A-T were unable to kill Renca-lacZ/ErbB2 or MDA-MD468 cells in the presence of chloroquine. Also enzymatically active GrB lacking a cell targeting domain could not induce cell death.
GrB fusion proteins induce apoptotic morphology
Cytotoxic activity of GrB-T and GrB-5 was also tested on A431 tumor cells that expresses both target receptors. In the presence of chloroquine, treatment of the cells for 14 h with GrB-T or GrB-5, but not unmodified GrB resulted in concentration-dependent cell killing quantified in MTT assays (Figure 5a). When cellular morphology was analyzed, A431 cells treated with GrB-T or GrB-5 displayed typical signs of apoptosis indicated by membrane blebbing and formation of apoptotic bodies (Figure 5b). In addition, chromatin condensation and fragmentation of the nuclei comparable to the effects induced by staurosporine could be detected after incubation of the cells with enzymatically active fusion proteins, but not upon treatment with GrBS183A-T or GrBS183A-5 (Figure 5c). Similar results were found with GrB-T for MDA-MB468 but not for MDA-MB453 cells, and with GrB-5 for Renca-lacZ/ErbB2 but not for Renca-lacZ cells. Signs of apoptosis could be observed as early as 2 h after addition of fusion proteins, which corresponds well with the kinetics described for the GrB/perforin system (data not shown).
GrB-5 and GrB-T activate endogenous caspases
We analyzed activation of endogenous caspase-3 in cytoplasmic extracts of A431 cells treated with GrB-5 or GrB-T, using the colorimetric caspase-3 peptide substrate Ac-DEVD-pNA. In addition, we investigated activation of caspases-8 and -9 acting upstream of caspase-3, with the fluorimetric peptide substrates Ac-IETD-AFC (caspase-8) and Ac-LEHD-AFC (caspase-9). All three caspases were activated following treatment of A431 cells with GrB-5 or GrB-T in the presence of chloroquine (Figure 6a). In the absence of the endosomolytic reagent, only background activities were found. Caspase activation was dependent on both, specific cell recognition and release of GrB fusion proteins from the endosomal compartment, since independent from the presence or absence of chloroquine, GrB lacking a cell targeting domain did not induce activation of the caspases. As expected, addition of the broad-range caspase inhibitor zVAD-fmk to the cells completely blocked caspase activities.
Chimeric GrB proteins cleave endogenous procaspase-3
Processing of endogenous caspase-3 in A431 cells treated with GrB-5 or GrB-T was analyzed by immunoblotting with a mAb recognizing an epitope at the N-terminus of caspase-3. In the absence of zVAD-fmk, both p20 and p17 caspase-3 fragments were detected indicating cleavage and activation of caspase-3 (Figure 6b). In the presence of zVAD-fmk, caspase-3 p20 subunit was still produced, but p17 was absent. This is in agreement with a mechanism relying on GrB activity for initial cleavage of caspase-3 to generate p20, followed by autocatalytic processing to yield p17.7 Only this latter step could be blocked by the caspase inhibitor zVAD-fmk. Confirming the results obtained in the enzymatic assays, specific cell recognition and endosome release were required to allow GrB access to caspase-3. Treatment of the cells with unmodified GrB, or retargeted GrB in the absence of chloroquine did not result in caspase-3 cleavage.
To investigate the effect of caspase inhibition on cell killing by retargeted GrB, A431 cells were treated with GrB-5 and chloroquine in the presence or absence of zVAD-fmk for 14 h, before cell viability was determined in an MTT assay (Figure 6c). Importantly, while inhibition of caspases reduced cell killing by GrB-5, significant cytotoxic activity was still observed indicating a contribution of caspase-independent mechanisms to GrB-induced cell death.
Recombinant antibody or growth factor toxins combine specific recognition of tumor cells with selective delivery of a potent cytotoxic effector molecule.18, 32 However, due to the bacterial or plant origin of their effector domain, patients treated with such molecules can develop neutralizing antitoxin antibodies, which precludes prolonged or repeated treatment cycles that might be necessary to achieve long-lasting therapeutic effects. Consequently, attempts are being made to reduce immunogenicity and employ cytotoxic effector functions of human origin for the construction of immunotoxin-like molecules. Here, we have derived novel chimeric proteins which carry human GrB as an apoptosis-inducing effector domain, and performed a detailed analysis of their in vitro activities. Specific targeting of GrB to tumor cells expressing high levels of the cellular proto-oncogenes EGFR or ErbB2 was achieved by fusion to the EGFR ligand TGFα or an ErbB2-specific scFv antibody fragment, and resulted in selective and efficient cell killing.
Different strategies have been proposed to exploit the process of cellular self-destruction for the ordered elimination of tumor cells. One approach is based on the fusion of tumor-specific cell-targeting domains to cell-death inducing cytokines such as tumor necrosis factor, CD95L or TRAIL.33 These cytokines act via death receptors on the tumor cell surface, and are therefore dependent on an intact extrinsic apoptosis pathway in the target cell. Owing to its ability to bypass common apoptosis resistance mechanisms in tumor cells,34 the serine protease GrB is emerging as a promising alternative effector function for immunotoxin-like molecules. GrB acts more downstream in the apoptosis cascade, and similar to recombinant toxins, functions via an enzymatic activity. It shares the substrate specificity of caspases and cleaves both, cellular caspases and various caspase target proteins.6, 7, 8, 9, 10, 11 Like an effector caspase, GrB activates the apoptosis machinery directly and at different levels. Therefore, cell death can be induced even if one pathway is blocked.1, 2 GrB has previously been employed in a fusion protein containing VEGF to target endothelial cells,21 and in chimeric proteins or immunoconjugates carrying antibody fragments for recognition of cancer cells via binding to a melanoma antigen or Lewis Y.22, 23 These recombinant GrB proteins were expressed in E. coli as inactive precursors, requiring in vitro cleavage after purification from bacterial lysates, and in one case also refolding to yield enzymatically active molecules. In another approach, the problem to produce a functional tumor-specific GrB fusion protein was solved by coincubating tumor cells with engineered T cells releasing such a molecule.35
We have followed a different strategy expressing the ErbB2-specific GrB-5 and EGFR-specific GrB-T molecules as secreted proteins in the yeast P. pastoris, thereby bypassing the need for refolding or in vitro activation, and resulting in large amounts of active recombinant proteins after a single purification step. Attachment of the C-terminal antibody and growth factor domains did not affect enzymatic activity of GrB. The chimeric GrB-5 and GrB-T molecules were able to cleave a synthetic GrB substrate and recombinant procaspase-3 as a natural target protein in a manner indistinguishable from unmodified GrB. Both fusion proteins were bifunctional, in addition to enzymatic activity also displaying specific binding to cells expressing high levels of the ErbB2 or EGFR target receptors. When GrB-5 was directly injected into the cytosol of tumor cells, we observed induction of apoptosis, which was strictly dependent on enzymatic GrB activity. GrB-5 and GrB-T added from the outside, however, were unable to kill ErbB2 or EGFR expressing tumor cells unless an endosomolytic activity was present.
Wild-type GrB is able to internalize into target cells, but localizes in vesicular structures inside the cytoplasm where it remains inactive.4, 36 Induction of apoptosis is only observed after the addition of perforin, which is thought to liberate GrB from these vesicles, allowing access of the protease to the cytosol. Also, GrB-5 and GrB-T were found to accumulate in intracellular vesicles without affecting cell survival. However, when the endosomolytic reagent chloroquine was present, GrB-5 and GrB-T were able to kill tumor cells at low concentrations. Importantly, this cell killing activity still required interaction with ErbB2 or EGFR target receptors and enzymatic activity of the GrB domain. Chloroquine has successfully been employed as an endosome release agent in animal models,37 and is being used as a drug for the treatment of malaria and other diseases in humans.38 Therefore, a requirement for cotreatment with chloroquine might not severely limit therapeutic applicability of GrB fusion proteins. Chloroquine accumulates in acidic compartments such as late endosomes and lysosomes, where it interferes with the pH equilibrium, finally leading to osmotic rupture of the vesicles.29 Therefore, retargeting of GrB to ErbB2 or EGFR must have resulted in routing to an acidic environment sensitive to chloroquine, as expected upon uptake of the fusion proteins via classical receptor-mediated endocytosis, but not typical for wild-type GrB. The membrane-disrupting potential of perforin is strongly decreased at pH values below 7,39 making it unlikely that its role is to release GrB from late endosomes or lysosomes. Furthermore, while unmodified GrB expressed in yeast was also found in intracellular vesicles when added to cells at high concentrations (unpublished data), these vesicles did not belong to a chloroquine-sensitive, acidic compartment. The endosomolytic reagent was unable to release unmodified GrB into the cytosol indicated by a lack of cytotoxic activity.
Selective cytotoxic activity was also described for bacterially expressed GrB fusion proteins targeting cell surface antigens other than ErbB2 or EGFR.21, 22, 23 Thereby no endosomolytic activity was provided, suggesting different intracellular routing of chimeric GrB molecules depending on the type of target receptor. However, also in these cases addition of an endosomolytic reagent might have been beneficial, indicated by the slower kinetics of apoptosis induction and cell killing, and the requirement for 10–300 times higher protein concentrations to achieve effects similar to GrB-5 and GrB-T.21, 22, 23 The requirement for effective endosome release was also shown for a chimeric GrB protein which similar to GrB-5 targets ErbB2, but in an approach for adoptive cell therapy was expressed in gene modified T cells. There the translocation domain of a bacterial toxin was included in the molecule to achieve cytoplasmic delivery of an active GrB fragment in target cells.35 In the presence of chloroquine, GrB-5 and GrB-T were able to specifically kill target cells with IC50 values in the picomolar to nanomolar range, whereas nontarget cells were not affected at considerably higher concentrations. These cytotoxic activities of the chimeric GrB derivatives are comparable to those of Pseudomonas exotoxin A fusion proteins which employ the same cell targeting domains.20, 28 Importantly, while such immunotoxins require incubation times of 40 h for maximum cell killing, high cytotoxic activity of the GrB fusion proteins was found after 14 h of incubation, and apoptotic morphology of target cells was observed as early as 2 h after addition of chimeric GrB molecules (data not shown), following kinetics similar to the GrB/perforin system.
A more detailed analysis of the events following treatment with GrB-5 and GrB-T was performed in A431 cells which carry both target receptors. Upon treatment of the cells with chimeric GrB proteins and chloroquine we observed hallmarks of apoptosis such as activation of initiator and effector caspases, chromatin condensation and formation of apoptotic bodies. Both, p20 and p17 caspase-3 fragments were generated, demonstrating cleavage and activation of endogenous caspase-3. In the presence of the broad-range caspase inhibitor zVAD-fmk only p20 subunit was produced, which is in agreement with a mechanism that relies on GrB activity for initial cleavage of caspase-3 to generate p20, followed by autocatalytic processing to yield p17.7 Importantly, even in the presence of the caspase inhibitor A431 cells were killed by GrB-5, albeit to a lesser extent. This ability of GrB fusion proteins to also initiate caspase-independent cell death pathways, possibly through cleavage of Bid or ICAD,13, 14 could be relevant for elimination of tumor cells with a block in caspase-dependent apoptosis.
Our data show that bifunctional, immunotoxin-like proteins employing human GrB as an effector domain can be readily expressed at high yields in the yeast P. pastoris. Upon specific binding to ErbB2 or EGFR on the surface of tumor cells, the chimeric molecules are internalized and can be released into the cytosol by an endosomolytic reagent, resulting in rapid and efficient cell killing. These reagents might be useful to study GrB-induced apoptosis without the requirement for perforin, but also hold promise for further development as targeted therapeutics of human origin.
Materials and Methods
Construction of GrB fusion proteins
A cDNA fragment encoding mature human GrB was amplified by PCR with the oligonucleotides 5′-GrB 5′-ATTCTCGAGAAAAGAATCATCGGGGGACATGAG-3′ and 3′-GrB 5′-TTTGCTAGCCCGTAGCGTTTCATGG-3′ from full-length GrB cDNA. The PCR product was fused to a sequence encoding a myc and a His6 tag, and subcloned into the yeast vector pPIC9 (Invitrogen, Karlsruhe, Germany), resulting in plasmid pPIC9-GrB. Likewise, fusion genes encoding the GrB domain followed by a (Gly4Ser)4 linker, an internal His6 tag, the ErbB2-specific single-chain antibody fragment scFv(FRP5),19 or the EGFR ligand TGFα,20 and C-terminal myc and His6 tags were assembled in pPIC9, resulting in plasmids pPIC9-GrB-5 and pPIC9-GrB-T. Enzymatically inactive GrB mutants were derived from constructs encoding active enzyme by site directed mutagenesis via PCR using the oligonucleotide primers S183A-s 5′-CCTTTAAGGGGGACGCTGGAGGCCCTCTTG-3′ and S183A-as 5′-CAAGAGGGCCTCCAGCGTCCCCCTTAAAGG-3′.
Expression and purification of recombinant proteins
P. pastoris GS115 cells (Invitrogen) were transformed with pPIC9 plasmids via electroporation, and positive clones were selected according to the manufacturer's instructions. Single colonies were grown in 100 ml buffered (pH 8) glycerol complex medium for 2 days at 30°C. For induction of expression, cultures were diluted 10-fold in methanol-containing buffered (pH 8) methanol complex medium to an OD600 of one, and cultured for another 4 days at 25°C. Yeast cells were removed by centrifugation, supernatants were adjusted to pH 8, and applied to a Ni-NTA superflow column (Qiagen, Hilden, Germany). Specifically bound proteins were eluted with 250 mM imidazole, 1 M NaCl in PBS, pH 8. Protein fractions containing GrB proteins were identified by SDS-PAGE and immunoblotting with myc-tag-specific antibody 9E10, or GrB-specific mAb 2C5 (Santa Cruz Biotechnology, Heidelberg, Germany), pooled, concentrated, dialyzed against PBS and stored until use at −80°C.
GrB activity assays
Chimeric GrB molecules were incubated for 1 h at 37°C in 96-well plates with 200 μM synthetic peptide substrate Ac-IETD-pNA (Alexis, Grünberg, Germany) and reaction buffer (10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) in a total volume of 100 μl per sample. Cleavage of substrate was quantified by measuring absorbance at 405 nm with a microplate reader.
Analysis of binding and uptake of chimeric GrB proteins
MDA-MB468 and MDA-MB453 human breast carcinoma cells, A431 epidermoid cancer cells (ATCC), and murine Renca-lacZ and Renca-lacZ/ErbB2 cells were cultured as described.20, 28 For FACS analysis, 3 × 105 trypsinized cells were incubated with 1.5 μg of GrB-T, GrBS183A-T, GrB-5 or GrBS183A-5 for 1 h at 4°C. Bound fusion proteins were detected upon subsequent incubation of the cells with 1.5 μg of myc-tag-specific antibody 9E10 followed by 1 : 50 diluted phycoerythrin-conjugated goat anti-mouse IgG (Jackson Immuno Research, West Grove, PA, USA) in PBS at 4°C using a FACScan flow cytometer (Beckton Dickinson, Heidelberg, Germany). To investigate uptake of GrB-5 and GrB-T, A431 cells were grown on coverslips and treated for 1 h at 37°C with 10 μg/ml of the proteins in normal growth medium. Cells were washed, and incubated for another 1.5 h in fresh medium. Then cells were fixed with 4% para-formaldehyde in PBS for 10 min, permeabilized in 0.1% Triton X-100 in PBS for 5 min, and incubated with 500 ng/ml GrB-specific mAb 2C5 in PBS, 3% BSA, followed by Alexa Fluor 488 donkey anti-mouse IgG (Molecular Probes, Leiden, The Netherlands) in PBS, 3% BSA. Then samples were analyzed with a Leica TCS SL laser scanning microscope (Leica Mikrosysteme, Bensheim, Germany). Microinjection of GrB fusion proteins into the cytosol of Renca-lacZ cells was carried out following established procedures.40
Cell viability assays
Cells were seeded in 96-well plates at a density of 1.5 to 2 × 104 cells/well and incubated for 14 h at 37°C with purified GrB proteins in triplicate in the absence or presence of 50 or 100 μM chloroquine. In some experiments, 100 μM of the broad-range caspase inhibitor zVAD-fmk (Alexis) were included. The relative number of viable cells in comparison to cells grown without GrB proteins was determined in MTT assays as described.20 To compete binding to ErbB2 and EGFR, cells were preincubated for 30 min with ErbB2-specific mAb FRP530 or recombinant ErbB2 protein,31 or the antagonistic anti-EGFR antibody C225,17 before addition of chimeric GrB molecules and determination of cell viability.
A431 cells were seeded in 96-well plates and incubated for 14 h at 37°C with 1 μg/ml of GrB-5, GrB-T, or enzymatically inactive fusion proteins. As a positive control for apoptotic morphology of nuclei, cells were treated with 1 μM of staurosporine. Adherent cells recovered by trypsination and detached dead cells from sample supernatants were pelleted by centrifugation, resuspended in 50 μl Hoechst staining solution (5 μg/ml Hoechst 33342, 1 μg/ml propidium iodide in PBS), incubated for 10 min at room temperature in the dark, and analyzed using a Nikon Eclipse TE300 fluorescence microscope.
Activation of endogenous caspases
A431 cells were incubated for 14 h at 37°C with GrB fusion proteins in the absence or presence of 100 μM chloroquine. Control samples were in addition treated with 100 μM of zVAD-fmk. Cells were lysed in 200 μl NETN buffer (20 mM Tris pH 8, 100 mM NaCl, 1 mM EDTA, 0.5 % NP-40, 10% glycerol, 1 mM DTT) for 15 min on ice, and cell debris was removed by centrifugation. Amounts of cell extracts corresponding to 50 μg of total proteins were analyzed by SDS-PAGE and immunoblotting with caspase-3 specific mAb E-8 (Santa Cruz Biotechnology) followed by HRP-conjugated secondary antibody and chemiluminescent detection with the ECL kit (Amersham Biosciences, Freiburg, Germany). Enzymatic activity of caspase-3 was determined by incubating 50 μg of total cellular proteins for 14 h at 37°C with 266 μM of the colorimetric caspase-3 substrate Ac-DEVD-pNA (Alexis) followed by measuring the absorbance at 405 nm. Enzymatic activity of caspases-8 and -9 was determined by incubating 20 μg of total cellular proteins for 2 h at 37°C with 37 μM of the fluorimetric caspase-8 substrate Ac-IETD-AFC, or caspase-9 substrate Ac-LEHD-AFC (Alexis), in a total volume of 150 μl in reaction buffer (100 mM Tris pH 8, 10% sucrose, 10 mM DTT, 150 mM NaCl, 0.1% CHAPS). Fluorescence was measured with a Bio-Rad Fluoromark™ microplate reader (Bio-Rad, Munich, Germany).
epidermal growth factor receptor
single-chain antibody fragment
Barry M and Bleackley RC (2002) Cytotoxic T lymphocytes: all roads lead to death. Nat. Rev. Immunol. 2: 401–409
Russell JH and Ley TJ (2002) Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 20: 323–370
Heusel JW, Wesselschmidt RL, Shresta S, Russell JH and Ley TJ (1994) Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76: 977–987
Froelich CJ, Orth K, Turbov J, Seth P, Gottlieb R, Babior B, Shah GM, Bleackley RC, Dixit VM and Hanna W (1996) New paradigm for lymphocyte granule-mediated cytotoxicity. Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis. J. Biol. Chem. 271: 29073–29079
Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, Houtzager VM, Nordstrom PA, Roy S, Vaillancourt JP, Chapman KT and Nicholson DW (1997) A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 272: 17907–17911
Darmon AJ, Nicholson DW and Bleackley RC (1995) Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 377: 446–448
Martin SJ, Amarante-Mendes GP, Shi L, Chuang TH, Casiano CA, O'Brien GA, Fitzgerald P, Tan EM, Bokoch GM, Greenberg AH and Green DR (1996) The cytotoxic cell protease granzyme B initiates apoptosis in a cell-free system by proteolytic processing and activation of the ICE/CED-3 family protease, CPP32, via a novel two-step mechanism. EMBO J. 15: 2407–2416
Medema JP, Toes RE, Scaffidi C, Zheng TS, Flavell RA, Melief CJ, Peter ME, Offringa R and Krammer PH (1997) Cleavage of FLICE (caspase-8) by granzyme B during cytotoxic T lymphocyte-induced apoptosis. Eur. J. Immunol. 27: 3492–3498
Yang X, Stennicke HR, Wang B, Green DR, Janicke RU, Srinivasan A, Seth P, Salvesen GS and Froelich CJ (1998) Granzyme B mimics apical caspases. Description of a unified pathway for trans-activation of executioner caspase-3 and -7. J. Biol. Chem. 273: 34278–34283
Adrain C, Murphy BM and Martin SJ (2005) Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease granzyme B. J. Biol. Chem. 280: 4663–4673
Andrade F, Roy S, Nicholson D, Thornberry N, Rosen A and Casciola-Rosen L (1998) Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis. Immunity 8: 451–460
Barry M, Heibein JA, Pinkoski MJ, Lee SF, Moyer RW, Green DR and Bleackley RC (2000) Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. Mol. Cell Biol. 20: 3781–3794
Waterhouse NJ, Sedelies KA, Browne KA, Wowk ME, Newbold A, Sutton VR, Clarke CJ, Oliaro J, Lindemann RK, Bird PI, Johnstone RW and Trapani JA (2005) A central role for bid in Granzyme B-induced apoptosis. J. Biol. Chem. 280: 4476–4482
Thomas DA, Du C, Xu M, Wang X and Ley TJ (2000) DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. Immunity 12: 621–632
Olayioye MA, Neve RM, Lane HA and Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19: 3159–3167
Yarden Y and Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2: 127–137
Mendelsohn J and Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550–6565
Wels W, Biburger M, Müller T, Dälken B, Giesübel U, Tonn T and Uherek C (2004) Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors. Cancer Immunol. Immunother. 53: 217–226
Wels W, Harwerth IM, Mueller M, Groner B and Hynes NE (1992) Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res. 52: 6310–6317
Schmidt M, Vakalopoulou E, Schneider DW and Wels W (1997) Construction and functional characterization of scFv(14E1)-ETA – a novel, highly potent antibody-toxin specific for the EGF receptor. Br. J. Cancer 75: 1575–1584
Liu Y, Cheung LH, Thorpe P and Rosenblum MG (2003) Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: directed apoptotic events in vascular endothelial cells. Mol. Cancer Ther. 2: 949–959
Liu Y, Cheung LH, Hittelman WN and Rosenblum MG (2003) Targeted delivery of human pro-apoptotic enzymes to tumor cells: in vitro studies describing a novel class of recombinant highly cytotoxic agents. Mol. Cancer Ther. 2: 1341–1350
Kurschus FC, Kleinschmidt M, Fellows E, Dornmair K, Rudolph R, Lilie H and Jenne DE (2004) Killing of target cells by redirected granzyme B in the absence of perforin. FEBS Lett. 562: 87–92
Caputo A, James MN, Powers JC, Hudig D and Bleackley RC (1994) Conversion of the substrate specificity of mouse proteinase granzyme B. Nat. Struct. Biol. 1: 364–367
Hoffmann M, Schmidt M and Wels W (1998) Activation of EGF receptor family members suppresses the cytotoxic effects of tumor necrosis factor-alpha. Cancer Immunol. Immunother. 47: 167–175
Dressel R, Raja SM, Honing S, Seidler T, Froelich CJ, von Figura K and Gunther E (2004) Granzyme-mediated cytotoxicity does not involve the mannose 6-phosphate receptors on target cells. J. Biol. Chem. 279: 20200–20210
Kurschus FC, Bruno R, Fellows E, Falk CS and Jenne DE (2005) Membrane receptors are not required to deliver granzyme B during killer cell attack. Blood 105: 2049–2058
Maurer-Gebhard M, Schmidt M, Azemar M, Altenschmidt U, Stöcklin E, Wels W and Groner B (1998) Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. Cancer Res. 58: 2661–2666
Zenke M, Steinlein P, Wagner E, Cotten M, Beug H and Birnstiel ML (1990) Receptor-mediated endocytosis of transferrin-polycation conjugates: an efficient way to introduce DNA into hematopoietic cells. Proc. Natl. Acad. Sci. USA 87: 3655–3659
Harwerth IM, Wels W, Marte BM and Hynes NE (1992) Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J. Biol. Chem. 267: 15160–15167
Gerstmayer B, Altenschmidt U, Hoffmann M and Wels W (1997) Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene. J. Immunol. 158: 4584–4590
Kreitman RJ (2003) Recombinant toxins for the treatment of cancer. Curr. Opin. Mol. Ther. 5: 44–51
Wajant H, Gerspach J and Pfizenmaier K (2005) Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev. 16: 55–76
Ferrarini M, Imro MA, Sciorati C, Heltai S, Protti MP, Pellicciari C, Rovere P, Manfredi AA and Rugarli C (1999) Blockade of the Fas-triggered intracellular signaling pathway in human melanomas is circumvented by cytotoxic lymphocytes. Int. J. Cancer 81: 573–579
Zhao J, Zhang LH, Jia LT, Zhang L, Xu YM, Wang Z, Yu CJ, Peng WD, Wen WH, Wang CJ, Chen SY and Yang AG (2004) Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells. J. Biol. Chem. 279: 21343–21348
Shi L, Mai S, Israels S, Browne K, Trapani JA and Greenberg AH (1997) Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization. J. Exp. Med. 185: 855–866
Zhang X, Sawyer GJ, Dong X, Qiu Y, Collins L and Fabre JW (2003) The in vivo use of chloroquine to promote non-viral gene delivery to the liver via the portal vein and bile duct. J. Gene Med. 5: 209–218
Raynes K (1999) Bisquinoline antimalarials: their role in malaria chemotherapy. Int. J. Parasitol. 29: 367–379
Griffiths GM (2003) Endocytosing the death sentence. J. Cell Biol. 160: 155–156
Knauer SK, Carra G and Stauber RH (2005) Nuclear export is evolutionarily conserved in CVC paired-like homeobox proteins and influences protein stability, transcriptional activation, and extracellular secretion. Mol. Cell Biol. 25: 2573–2582
We thank Dr. Martin Zörnig for helpful suggestions and critical reading of the manuscript.
Edited by SJ Martin
About this article
Cite this article
Dälken, B., Giesübel, U., Knauer, S. et al. Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition. Cell Death Differ 13, 576–585 (2006). https://doi.org/10.1038/sj.cdd.4401773
- granzyme B
- EGF receptor
Cancer Cell International (2021)
Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B
Journal of Experimental & Clinical Cancer Research (2019)
Molecular Biology Reports (2019)
Cancer Chemotherapy and Pharmacology (2011)
Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells
Cancer Immunology, Immunotherapy (2008)